MétaCan
Menu
Retour à la cohorte
Enregistrement W1977141816 · doi:10.1001/jamaneurol.2014.2157

Rarity of the Alzheimer Disease–Protective<i>APP</i>A673T Variant in the United States

2014· article· en· W1977141816 sur OpenAlexafffund
Li-San Wang, Adam C. Naj, Robert Graham, Paul K. Crane, Brian W. Kunkle, Carlos Cruchaga, Josue D. Gonzalez Murcia, Lisa Cannon‐Albright, Clinton T. Baldwin, Henrik Zetterberg, Kaj Blennow, Walter A. Kukull, Kelley M. Faber, Nicole Schupf, Maria C. Norton, JoAnn T. Tschanz, Ronald G. Munger, Christopher Corcoran, Ekaterina Rogaeva, Chiao‐Feng Lin, Beth A. Dombroski, Laura B. Cantwell, Amanda Partch, Otto Valladares, Håkon Håkonarson, Peter St George‐Hyslop, Robert C. Green, Alison Goate, Tatiana Foroud, Regina M. Carney, Eric B. Larson, Timothy W. Behrens, John Kauwe, Jonathan L. Haines, Lindsay A. Farrer, Margaret A. Pericak‐Vance, Richard Mayeux, Gerard D. Schellenberg, Marilyn S. Albert, Roger L. Albin, Liana G. Apostolova, Steven E. Arnold, Robert W. Barber, M. Michael Barmada, Lisa L. Barnes, Thomas G. Beach, James T. Becker, Gary W. Beecham, Duane Beekly, David A. Bennett, Eileen H. Bigio, Thomas D. Bird, Deborah Blacker, Bradley F. Boeve, James D. Bowen, Adam Boxer, James R. Burke, Joseph D. Buxbaum, Nigel J. Cairns, Chuanhai Cao, Chris Carlson, Steven L. Carroll, Helena C. Chui, David G. Clark, David H. Cribbs, Elizabeth Crocco, Charles DeCarli, Steven T. DeKosky, F. Yesim Demirci, Malcolm Dick, Dennis W. Dickson, Ranjan Duara, Nilüfer Ertekin‐Taner, Kenneth B. Fallon, Martin R. Farlow, Steven H. Ferris, Matthew P. Frosch, Douglas Galasko, Mary Ganguli, Marla Gearing, Daniel H. Geschwind, Bernardino Ghetti, John R. Gilbert, Jonathan D. Glass, Neill R. Graff‐Radford, John H. Growdon, Ronald L. Hamilton, Kara L. Hamilton‐Nelson, Lindy E. Harrell, Elizabeth Head, Lawrence S. Honig, Christine M. Hulette, Bradley T. Hyman, Gail P. Jarvik, Gregory A. Jicha, Lee‐Way Jin, Gyungah Jun, M. Ilyas Kamboh, Anna Karydas, Jeffrey Kaye, Ronald Kim, Edward H. Koo, Neil W. Kowall, Joel H. Kramer, Patricia Kramer, Frank M. LaFerla, James J. Lah, James B. Leverenz, Allan I. Levey, Ge Li, Andrew P. Lieberman, Oscar L. López, Kathryn L. Lunetta, Constantine G. Lyketsos, Wendy J. Mack, Daniel Marson, Eden R. Martin, Frank Martiniuk, Deborah C. Mash, Eliezer Masliah, Wayne C. McCormick, Susan M. McCurry, Andrew McDavid, Ann C. McKee, Marsel Mesulam, Bruce L. Miller, Carol A. Miller, Joshua W. Miller, Thomas J. Montine, John C. Morris, Jill R. Murrell, John Olichney, Joseph E. Parisi, William Perry, Elaine R. Peskind, Ronald Petersen, Aimee Pierce, Wayne W. Poon, Huntington Potter, Joseph F. Quinn, Ashok Raj, Murray A. Raskind, Eric M. Reiman, ‌Barry Reisberg, Christiane Reitz, John M. Ringman, Erik D. Roberson, Howard J. Rosen, Roger N. Rosenberg, Mary Sano, Andrew J. Saykin, Julie A. Schneider, Lon S. Schneider, William W. Seeley, Amanda Smith, Joshua A. Sonnen, Salvatore Spina, Robert A. Stern, Rudolph E. Tanzi, Tricia A. Thornton‐Wells, John Q. Trojanowski, Juan C. Troncoso, Debby W. Tsuang, Vivianna M. Van Deerlin, Linda J. Van Eldik, Badri N. Vardarajan, Harry V. Vinters, Jean Paul Vonsattel, Sandra Weıntraub, Kathleen A. Welsh‐Bohmer, Jennifer Williamson, Sarah Wishnek, Randall L. Woltjer, Clinton B. Wright, Steven G. Younkin, Chang‐En Yu, Lei Yu

Notice bibliographique

RevueJAMA Neurology · 2014
Typearticle
Langueen
DomaineMedicine
ThématiqueAlzheimer's disease research and treatments
Établissements canadiensOccupational Cancer Research CentreUniversity of Toronto
Organismes subventionnairesNIH Clinical CenterNational Center for Research ResourcesNational Cancer InstituteNational Human Genome Research InstituteNational Heart, Lung, and Blood InstituteNational Institute on AgingNational Center for Advancing Translational SciencesMedical Research CouncilCenter for Clinical and Translational Science, University of Alabama at BirminghamLeonard M. Miller School of Medicine, University of MiamiUniversity of California, IrvineNational Institute of Mental HealthFeinberg School of MedicineUniversity of California, San FranciscoCanadian Institutes of Health ResearchUniversity of California, Los AngelesAlzheimer's Disease Research Center, Emory UniversityNational Institutes of HealthUniversity of California, DavisHoward Hughes Medical InstituteEisaiUSF Health Byrd Alzheimer's InstituteNational Institute of Neurological Disorders and StrokeUniversity of PittsburghJohns Hopkins UniversityUniversity of WashingtonUCB PharmaEmory UniversityUniversity of PennsylvaniaUniversity of MiamiYork UniversityPfizerNorthwestern UniversityBiogenMassachusetts General HospitalGenentechUniversity of South FloridaSanofiWellcome TrustUniversity of Southern CaliforniaRush UniversityLeonard M. Miller School of MedicineUniversity of California, San DiegoU.S. Department of Veterans AffairsAstraZenecaEli Lilly and Company
Mots-clésCohortAlzheimer's diseaseCase-control studyDiseaseMedicinePopulationGenotypeAllele frequencyGenotypingCohort studyGerontologyInternal medicinePsychologyGeneticsBiologyGene

Résumé

récupéré en direct d'OpenAlex

IMPORTANCE: Recently, a rare variant in the amyloid precursor protein gene (APP) was described in a population from Iceland. This variant, in which alanine is replaced by threonine at position 673 (A673T), appears to protect against late-onset Alzheimer disease (AD). We evaluated the frequency of this variant in AD cases and cognitively normal controls to determine whether this variant will significantly contribute to risk assessment in individuals in the United States. OBJECTIVE: To determine the frequency of the APP A673T variant in a large group of elderly cognitively normal controls and AD cases from the United States and in 2 case-control cohorts from Sweden. DESIGN, SETTING, AND PARTICIPANTS: Case-control association analysis of variant APP A673T in US and Swedish white individuals comparing AD cases with cognitively intact elderly controls. Participants were ascertained at multiple university-associated medical centers and clinics across the United States and Sweden by study-specific sampling methods. They were from case-control studies, community-based prospective cohort studies, and studies that ascertained multiplex families from multiple sources. MAIN OUTCOMES AND MEASURES: Genotypes for the APP A673T variant were determined using the Infinium HumanExome V1 Beadchip (Illumina, Inc) and by TaqMan genotyping (Life Technologies). RESULTS: The A673T variant genotypes were evaluated in 8943 US AD cases, 10 480 US cognitively normal controls, 862 Swedish AD cases, and 707 Swedish cognitively normal controls. We identified 3 US individuals heterozygous for A673T, including 1 AD case (age at onset, 89 years) and 2 controls (age at last examination, 82 and 77 years). The remaining US samples were homozygous for the alanine (A673) allele. In the Swedish samples, 3 controls were heterozygous for A673T and all AD cases were homozygous for the A673 allele. We also genotyped a US family previously reported to harbor the A673T variant and found a mother-daughter pair, both cognitively normal at ages 72 and 84 years, respectively, who were both heterozygous for A673T; however, all individuals with AD in the family were homozygous for A673. CONCLUSIONS AND RELEVANCE: The A673T variant is extremely rare in US cohorts and does not play a substantial role in risk for AD in this population. This variant may be primarily restricted to Icelandic and Scandinavian populations.

Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.

Comment cette classification a été obtenuedéplier

Prédiction distillée sur la base complète

Imitation des enseignants

Ni prévalence calibrée, ni vérité terrain. Validation humaine à venir. Apprise à partir de 10 348 étiquettes directes de Codex et de 10 348 étiquettes directes de Gemma. Le mode candidate est l'union des têtes enseignantes seuillées; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont ni des étiquettes humaines ni des étiquettes directes de modèles de pointe.

score de la tête « metaresearch » (Codex)0,000
score de la tête « metaresearch » (Gemma)0,000
Version: codex-gemma-dda1882f352aStatut de validation: machine_predicted_unvalidated
Catégories candidatesaucune
Catégories consensuellesaucune
DomaineSignal candidat: aucune · Signal consensuel: aucune
Devis d'étudeSignal candidat: Observationnel · Signal consensuel: Observationnel
GenreSignal candidat: Empirique · Signal consensuel: Empirique
Score de désaccord entre enseignants0,061
Score d'incertitude au seuil0,307

Scores Codex et Gemma par catégorie

CatégorieCodexGemma
Métarecherche0,0000,000
Méta-épidémiologie (sens strict)0,0000,000
Méta-épidémiologie (sens large)0,0000,000
Bibliométrie0,0000,000
Études des sciences et des technologies0,0000,000
Communication savante0,0000,000
Science ouverte0,0000,000
Intégrité de la recherche0,0000,001
Charge utile insuffisante (le modèle a refusé de juger)0,0000,000

Scores machine (provisoires)

Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.

Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.

Tête enseignante Opus0,025
Tête enseignante GPT0,289
Écart entre enseignants0,264 · la distance entre les deux têtes enseignantes sur ce seul travail
Statut de validationscore_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découle

Classification

machine, non validée

Prédiction automatique; un appel candidat d’une seule tête enseignante, pas un consensus.

Les modèles n’ont appliqué aucune catégorie : rien dans la taxonomie ne correspondait à ce travail.
Devis d'étudeObservationnel
Domainenon disponible
GenreEmpirique

Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».

En bref

Citations49
Publié2014
Routes d'admission2
Résumé présentoui

Explorer davantage

Même revueJAMA NeurologyMême sujetAlzheimer's disease research and treatmentsTravaux en français237 207